v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Cash flows from operating activities:          
Net income $ 36,456 $ 19,351 $ 92,380 $ 49,169  
Adjustments to reconcile net income to net cash flows from operating activities:          
Provision for credit losses on accounts receivable 100 800 530 1,422  
Reserve for product returns     2,672 2,979  
Provision for credit losses on notes receivable     3,996 0  
Inventory write-down     0 1,181 $ 1,400
Amortization on patents and tooling     657 965  
Amortization and depreciation 7,612 7,948 22,029 23,481  
Amortization of debt issuance costs     3,296 2,357  
Amortization of operating leases     9,425 8,540  
Deferred income taxes     (32,739) (42,612)  
Change in fair value of contingent liability     105 23  
Stock-based compensation     31,675 36,423  
Loss from investment in unconsolidated entity     203 0  
Changes in operating assets and liabilities (net of business acquisitions):          
Accounts receivable     6,425 11,048  
Inventory     21,195 2,750  
Other current and non-current assets     (5,034) 6,423  
Accounts payable, accrued expenses and other current liabilities     (4,904) 371  
Deferred revenue     4,126 4,507  
Operating lease liabilities     (9,171) (10,329)  
Other liabilities     3,287 (2,605)  
Cash flows from operating activities     150,153 96,093  
Cash flows used in investing activities:          
Business acquisition, net of cash acquired     0 (9,696)  
Additions to property and equipment     (7,865) (5,349)  
Issuances of notes receivable     (500) (300)  
Receipt of payments on notes receivable     38 40  
Capitalized software development costs     (1,128) (315)  
Purchase of investment in unconsolidated entities     (7,052) (200)  
Purchases of other intangible assets     (46) (5,915)  
Cash flows used in investing activities     (16,553) (21,735)  
Cash flows from / (used in) financing activities:          
Proceeds from issuance of convertible senior notes     500,000 0  
Payments of debt issuance costs     (14,834) 0  
Purchases of capped calls related to convertible senior notes     (63,050) 0  
Payments of deferred consideration for acquisitions     (7,269) (1,672)  
Purchases of treasury stock, including transaction costs     (75,000) (12,854)  
Payments of tax withholdings related to vesting of restricted stock units 0 0 (3,401) 0  
Purchases of redeemable noncontrolling interest     0 (832)  
Payments of acquired debt     0 (3,016)  
Issuances of common stock from equity-based plans     7,840 3,129  
Cash flows from / (used in) financing activities     344,286 (15,245)  
Effect of exchange rate changes on cash, cash equivalents and restricted cash     (290) (57)  
Net increase in cash, cash equivalents and restricted cash     477,596 59,056  
Cash, cash equivalents and restricted cash at beginning of the period     701,079 622,879 622,879
Cash, cash equivalents and restricted cash at end of the period 1,178,675 681,935 1,178,675 681,935 701,079
Reconciliation of cash, cash equivalents and restricted cash:          
Cash and cash equivalents 1,170,605 679,969 1,170,605 679,969 696,983
Restricted cash included in other current assets and other assets 8,070 1,966 8,070 1,966  
Total cash, cash equivalents and restricted cash $ 1,178,675 $ 681,935 $ 1,178,675 $ 681,935 $ 701,079